Ufp Technologies (UFPT) reported $603M in revenue for fiscal 2025, +19.5% year on year. That ranks #2103 by revenue among 2853 SEC filers and #203 in Healthcare. Net income was $68.3M, a net margin of 11.3%. Revenue has grown 17.1% a year on average since 2016 ($146M then). The fiscal 2025 balance sheet shows $655M in total assets, $20.3M in cash and $123M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $603M | +19.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $170M | +16.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $92.3M | +14.1% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $68.3M | +15.8% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $91.9M | +38.0% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $9.7M | −8.0% | FY20242024-12-31 |
| Total assetsAssets | $655M | +4.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $424M | +23.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $20.3M | +50.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $123M | −30.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $154M | $17.5M | Open → |
| Q2 20262026-06-30 | $174M | $20.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ufp Technologies Inc
- Ticker
- UFPT
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0000914156
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Opko HealthOPK | $607M | −$226M |
| InsmedINSM | $606M | −$1.3B |
| Transmedics GroupTMDX | $605M | $190M |
| Ufp TechnologiesUFPT | $603M | $68.3M |
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
| AlvotechALVO | $586M | $27.9M |
| BioventusBVS | $568M | $22.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ufp Technologies — Key figures |url=https://companiesranked.com/en/company/ufp-technologies |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ufp Technologies — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ufp-technologiesBibTeX
@misc{companiesranked-en-company-ufp-technologies-2026,
author = {{CompaniesRanked}},
title = {{Ufp Technologies — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ufp-technologies}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-012816 · February 27, 2026
{{cite web |title=Ufp Technologies — Key figures — 10-K (0001628280-26-012816) |url=https://www.sec.gov/Archives/edgar/data/914156/000162828026012816/ufpt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.